Want to see OKUR full AI Analyst Report?
Top Page
OnKure Therapeutics
(NASDAQ:OKUR)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.00
▼(-47.37% Downside)
Action:Reiterated
Date:10/20/26
The score is held down primarily by the lack of revenue and ongoing large losses/cash burn, plus clearly bearish technicals (below key moving averages and negative MACD). A low-debt balance sheet and stronger equity base provide some support, but not enough to offset the execution and funding risks typical of a development-stage biotech.
Positive Factors
Low Leverage and Improved Equity
Very low debt limits fixed financial obligations and reduces leverage risk, while the stronger equity base provides greater capacity to support development activities. This balance-sheet profile gives OnKure more flexibility than a similarly unprofitable biotech with substantial borrowings.
Negative Factors
No Revenue and Widening Losses
The absence of revenue leaves OnKure dependent on future clinical and commercial execution to create an economic return. Meanwhile, widening losses show that spending is increasing without an offsetting revenue base, making profitability an unresolved medium-term challenge.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage and Improved Equity
Very low debt limits fixed financial obligations and reduces leverage risk, while the stronger equity base provides greater capacity to support development activities. This balance-sheet profile gives OnKure more flexibility than a similarly unprofitable biotech with substantial borrowings.
Read all positive factors
OnKure Therapeutics (OKUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$105.09M
Dividend YieldN/A
Average Volume (3M)367.95K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue GrowthN/A
EPS Growth34.92%
CountryUS
Employees45
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.50
Shares Outstanding40,496,307
10 Day Avg. Volume295,000
30 Day Avg. Volume367,949
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-255.88
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$15.00Price Target Upside294.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.79
Revenue Forecast (FY)$333.33K
OnKure Therapeutics Business Overview & Revenue Model
Company Description
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developi...
How the Company Makes Money
null...
OnKure Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -203.00K | -830.00K | 0.00 | 0.00 | 0.00 | -50.00K |
| EBITDA | -57.90M | -58.69M | -51.71M | -34.75M | -29.13M | -39.72M |
| Net Income | -58.70M | -59.52M | -52.67M | -35.31M | -29.51M | -39.77M |
Balance Sheet | ||||||
| Total Assets | 179.35M | 62.12M | 114.91M | 35.73M | 16.00M | 154.02M |
| Cash, Cash Equivalents and Short-Term Investments | 176.39M | 59.05M | 110.76M | 29.88M | 11.54M | 147.67M |
| Total Debt | 926.00K | 549.00K | 1.08M | 674.00K | 637.00K | 0.00 |
| Total Liabilities | 7.25M | 5.93M | 11.08M | 137.58M | 70.42M | 6.81M |
| Stockholders Equity | 172.11M | 56.18M | 103.83M | -101.84M | -54.42M | 147.21M |
Cash Flow | ||||||
| Free Cash Flow | -47.86M | -51.87M | -51.17M | -34.79M | -28.09M | -38.18M |
| Operating Cash Flow | -47.84M | -51.83M | -51.12M | -34.55M | -26.95M | -37.98M |
| Investing Cash Flow | -9.89M | -46.00K | 15.87M | -246.00K | -1.13M | -23.38M |
| Financing Cash Flow | 140.86M | 163.00K | 116.13M | 53.13M | 26.46M | 132.41M |
OnKure Therapeutics Technical Analysis
Neutral
3.80
Price Trends
2.99
Negative
3.61
Negative
3.62
Negative
Market Momentum
-0.14
Negative
50.14
Neutral
81.04
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OKUR, the sentiment is Neutral. The current price of 3.8 is above the 20-day moving average (MA) of 2.42, above the 50-day MA of 2.99, and above the 200-day MA of 3.62, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 50.14 is Neutral, neither overbought nor oversold. The STOCH value of 81.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OKUR.
OnKure Therapeutics Risk Analysis
OnKure Therapeutics disclosed 71 risk factors in its most recent earnings report. OnKure Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
OnKure Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $35.64M | 0.62 | 940.81% | ― | -48.76% | -3.02% | |
49 Neutral | $28.79M | -3.01 | -113.58% | ― | ― | ― | |
48 Neutral | $84.93M | -2.26 | -129.93% | ― | 306.42% | 70.84% | |
45 Neutral | $105.09M | -0.74 | -49.02% | ― | ― | 34.92% |
* Healthcare Sector Average
OKUR
OnKure Therapeutics
2.60
-0.73
-22.07%
IGC
IGC Pharma
0.25
-0.17
-40.34%
ELUT
Elutia
0.80
-0.09
-10.27%
RANI
Rani Therapeutics Holdings
0.61
-1.28
-67.78%
OnKure Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
OnKure Reprices Underwater Stock Options to Boost Retention
Neutral
Aug 13, 2026
On August 7, 2026, OnKure Therapeutics’ board approved a repricing of underwater stock options granted before January 1, 2025, with exercise prices at or above $10, affecting about 1.7 million shares, or roughly 40% of options under its equi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.